The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
The etiology of rheumatoid arthritis
Open accessAbstract
Rheumatoid arthritis is a heterogeneous disease, which can be, based on data combining genetic risk factors and autoantibodies, sub-classified into ACPA-positive and -negative RA. Presence of ACPA and RF as well as rising CRP-levels in some patients years before onset of clinical symptoms indicate that relevant immune responses for RA development are initiated very early. ACPA are highly specific for RA, whereas RF can also be found among healthy (elderly) individuals and patients with other autoimmune diseases or infection. The most important genetic risk factor for RA development, the shared epitope alleles, resides in the MHC class II region. Shared epitope alleles, however, only predispose to the development of ACPA-positive RA. Smoking is thus far the most important environmental risk factor associated with the development of RA. Studies on synovitis have shown the importance not only of adaptive but also of innate immune responses. In summary of the various results from immunological changes in blood and synovial tissue, the extension of the immune response from a diffuse myeloid to a lympho-myeloid inflammation appears to be associated with a more successful therapeutic response to biologics. With respect to advances in synovitis research, new targets for treatment against pathological subsets of immune cells or fibroblasts are already on the horizon. However, alternative strategies involving the microbiome may play an important role as well and research in this field is growing rapidly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Tak, P. P., Doorenspleet, M. E., de Hair, M. J. H., Klarenbeek, P. L., van Beers-Tas, M. H., van Kampen, A. H. C., van Schaardenburg, D., Gerlag, D. M., Baas, F., & de Vries, N. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211351 · Cited by 59
RetractedGregersen, P. K., Silver, J., & Winchester, R. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301102 · Cited by 2,599
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,578
Treating rheumatoid arthritis to target: recommendations of an international task force
Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123919 · Cited by 2,100
Self-citationRantapää‐Dahlqvist, S., de Jong, B. A. W., Berglin, E., Hallmans, G., Wadell, G., Stenlund, H., Sundin, U., & van Venrooij, W. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11223 · Cited by 1,953
Nielen, M. M. J., van Schaardenburg, D., Reesink, H. W., van de Stadt, R. J., van der Horst‐Bruinsma, I. E., de Koning, M. H. M. T., Habibuw, M. R., Vandenbroucke, J. P., & Dijkmans, B. A. C. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20018 · Cited by 1,861
Schellekens, G. A., de Jong, B. A., van den Hoogen, F. H., van de Putte, L. B., & van Venrooij, W. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1316 · Cited by 1,450
Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium, Zhang, F., Wei, K., Slowikowski, K., Fonseka, C. Y., Rao, D. A., Kelly, S., Goodman, S. M., Tabechian, D., Hughes, L. B., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0378-1 · Cited by 1,367
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
BIRAC Consortium, Stahl, E. A., YEAR Consortium, Raychaudhuri, S., Remmers, E. F., Xie, G., Eyre, S., Thomson, B. P., Li, Y., Kurreeman, F. A. S., et al. (2010) · Nature Genetics · doi:10.1038/ng.582 · Cited by 1,253
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Cited by
Management of Rheumatoid Arthritis: An Overview
Radu, A.-F., & Bungau, S. G. (2021) · Cells · doi:10.3390/cells10112857 · Cited by 1,089
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Epstein-Barr Virus and Systemic Autoimmune Diseases
Houen, G., & Trier, N. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587380 · Cited by 379
Liu, B., Wang, J., Li, Y.-Y., Li, K.-P., & Zhang, Q. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03018-6 · Cited by 293
Metadata
- Authors
- Scherer, H. U., Häupl, T., & Burmester, G. R.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 110
- Pages
- 102400
- ISSN
- 0896-8411 (ISSN-L)
- OpenAlex
- W3002498794
- Cited by
- 881
- References
- 138
- FWCI
- 64.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The etiology of rheumatoid arthritis. https://app.cochat.ai/papers/10.1016/j.jaut.2019.102400
- The paper
- Scherer, H. U., Häupl, T., & Burmester, G. R. (2020). The etiology of rheumatoid arthritis. Journal of Autoimmunity. https://doi.org/10.1016/j.jaut.2019.102400
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.